Serotonin is a survival factor for human multiple myeloma cells

2021 ◽  
Author(s):  
Harold Carter Davidson
Keyword(s):  
Multiple Myeloma ◽  
Myeloma Cells ◽  
Survival Factor ◽  
Human Multiple Myeloma

Phosphoproteomic analysis of primary human multiple myeloma cells

2010 ◽  
Vol 73 (7) ◽  
pp. 1381-1390 ◽  
Author(s):  
Feng Ge ◽  
Chuan-Le Xiao ◽  
Xing-Feng Yin ◽  
Chun-Hua Lu ◽  
Hui-Lan Zeng ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Myeloma Cells ◽  
Human Multiple Myeloma

β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells

2002 ◽  
Vol 30 (7) ◽  
pp. 711-720 ◽  
Author(s):  
Deepak Gupta ◽  
Klaus Podar ◽  
Yu-Tzu Tai ◽  
Boris Lin ◽  
Teru Hideshima ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Drug Resistance ◽  
Myeloma Cells ◽  
Plant Product ◽  
Human Multiple Myeloma

scholarly journals Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo

2016 ◽  
Vol 17 (11) ◽  
pp. 1927 ◽  
Author(s):  
Bingqian Xie ◽  
Zhijian Xu ◽  
Liangning Hu ◽  
Gege Chen ◽  
Rong Wei ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Jnk Pathway ◽  
Myeloma Cells ◽  
Human Multiple Myeloma

scholarly journals Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD40 Ligand Transgene

2009 ◽  
Vol 15 (15) ◽  
pp. 4847-4856 ◽  
Author(s):  
Margret S. Fernandes ◽  
Erica M. Gomes ◽  
Lindsay D. Butcher ◽  
Reuben Hernandez-Alcoceba ◽  
Dongkun Chang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Inhibition ◽  
Cd40 Ligand ◽  
Oncolytic Adenovirus ◽  
Myeloma Cells ◽  
Human Multiple Myeloma

scholarly journals Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells

2013 ◽  
Vol 2013 ◽  
pp. 1-13 ◽  
Author(s):  
Jinsil Jang ◽  
Soo-Jin Jeong ◽  
Hee-Young Kwon ◽  
Ji Hoon Jung ◽  
Eun Jung Sohn ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Treatment ◽  
Tyrosine Phosphatase ◽  
Combined Treatment ◽  
Parp Cleavage ◽  
Myeloma Cells ◽  
Stat3 Signaling Pathway ◽  
Human Multiple Myeloma ◽  
Induction Of Apoptosis ◽  
Apoptotic Activity

Background. Combination cancer therapy is one of the attractive approaches to overcome drug resistance of cancer cells. In the present study, we investigated the synergistic effect of decursin fromAngelica gigasand doxorubicin on the induction of apoptosis in three human multiple myeloma cells.Methodology/Principal Findings. Combined treatment of decursin and doxorubicin significantly exerted significant cytotoxicity compared to doxorubicin or decursin in U266, RPMI8226, and MM.1S cells. Furthermore, the combination treatment enhanced the activation of caspase-9 and -3, the cleavage of PARP, and the sub G1 population compared to either drug alone in three multiple myeloma cells. In addition, the combined treatment downregulated the phosphorylation of mTOR and its downstream S6K1 and activated the phosphorylation of ERK in three multiple myeloma cells. Furthermore, the combined treatment reduced mitochondrial membrane potential, suppressed the phosphorylation of JAK2, STAT3, and Src, activated SHP-2, and attenuated the expression of cyclind-D1 and survivin in U266 cells. Conversely, tyrosine phosphatase inhibitor pervanadate reversed STAT3 inactivation and also PARP cleavage and caspase-3 activation induced by combined treatment of doxorubicin and decursin in U266 cells.Conclusions/Significance. Overall, the combination treatment of decursin and doxorubicin can enhance apoptotic activity via mTOR and/or STAT3 signaling pathway in multiple myeloma cells.

Sign in / Sign up

Export Citation Format

Share Document